A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01205451
First received: September 3, 2010
Last updated: November 15, 2012
Last verified: October 2012
  Purpose

This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity. Qualified patients who complete GSK double-blind study 112958 will be enrolled. Subjects will receive a single treatment session of intramuscular GSK1358820 "200U or 240U (if thumb spasticity is present)". The subjects will be observed until 12 weeks post injection. Outcome measures include changes from baseline at every post injection visit as measured on the Modified Ashworth Scale (MAS), Disability Assessment Scale (DAS) and Global Assessment Scale. Safety parameters will be measured including adverse events, vital signs (pulse and blood pressure) and clinical laboratory tests (haematology, serum chemistry and urinanalysis).


Condition Intervention Phase
Spasticity, Post-Stroke
Drug: Botulinum toxin type A
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline at Week 6 and Week 12 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    The investigator or assessor extended the participant's wrist as quickly as possible to grade flexor muscle tone. The MAS wrist score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at Week 6 or Week 12 was calculated as the value at Week 6 or Week 12 minus the value at Baseline.


Secondary Outcome Measures:
  • Number of Participants Classified as Wrist Treatment Responders at Week 6 and Week 12 [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    Wrist treatment responders are defined as participants with a decrease in wrist flexor muscle tone of at least one point on the MAS from Baseline. The MAS wrist score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension).

  • Change From Baseline at Week 6 and Week 12 for Finger Flexor Muscle Tone as Measured on the MAS [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    The investigator or assessor extended the participant's finger as quickly as possible to grade the flexor muscle tone. The MAS finger score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at Week 6 or Week 12 was calculated as the value at Week 6 or Week 12 minus the value at Baseline.

  • Change From Baseline at Week 6 and Week 12 for Thumb Flexor Muscle Tone as Measured on the MAS [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    The investigator or assessor extended the participant's thumb as quickly as possible to grade the flexor muscle tone. The MAS thumb score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at Week 6 or Week 12 was calculated as the value at Week 6 or Week 12 minus the value at Baseline.

  • Change From Baseline at Week 6 and Week 12 for the Principal Measure as Assessed on the Disability Assessment Scale (DAS) [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    The investigator assessed 4 areas of disability, hygiene, pain, dressing, and limb posture, using the 4-point DAS (0=No functional disability to 3=Severe disability). Prior to the first dose, the investigator, in consultation with the participant, selected 1functional disability item (which had to have a score of 2 or greater as measured on the DAS, indicating moderate to severe disability) from the 4 areas of disability and assessed it as a principal measure. Change from Baseline at Week 6 or Week 12 was calculated as the value at Week 6 or Week 12 minus the value at Baseline.

  • Global Assessment Scale (GAS) Score as Evaluated by the Physician at Week 6 and Week 12 [ Time Frame: Week 6 and Week 12 ] [ Designated as safety issue: No ]
    The physician used the GAS to assess response to treatment at each visit after injection. The assessor was the same throughout the study period. GAS scores were assessed by using the 9-point GAS (-4, -3, -2, -1, -0, +1, +2, +3, +4; -4=very marked worsening, -0=unchanged, +4=very marked improvement) at Week 6 and Week 12.

  • GAS Score as Evaluated by the Care Giver or the Participant at Week 6 and Week 12 [ Time Frame: Week 6 and Week 12 ] [ Designated as safety issue: No ]
    The care giver or participant used the GAS to assess response to treatment at each visit after injection. The assessor was the same throughout the study period. GAS scores were assessed by using the 9-point GAS (-4, -3, -2, -1, -0, +1, +2, +3, +4; -4=very marked worsening, 0=unchanged, +4=very marked improvement) at Week 6 and Week 12.

  • Mean Change From Baseline in Red Blood Cell (RBC) Count at the Exit Visit [ Time Frame: Baseline (Day 0) and exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected and evaluated for RBC count at Baseline and at the exit visit. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in White Blood Cell (WBC) and Platelet Count at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected and evaluated for WBC count and platelet count at Baseline and at the exit visit. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in the Percentage of Neutrophils, the Percentage of Lymphocytes, the Percentage of Monocytes, the Percentage of Eosinophils, and the Percentage of Basophils at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected and evaluated for the percentage of neutrophils, lymphocytes, monocytes, eosinophils, and basophils comprising the total WBC count in the blood at Baseline and at the exit visit. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Hemoglobin Content at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected and evaluated for hemoglobin at Baseline and at the exit visit. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Hematocrit Value at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    The hematocrit, also called packed cell volume or erythrocyte volume fraction, is the volume percentage of red blood cells in the blood. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Total Protein and Albumin Values at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected for a biochemical test of total protein and albumin, at Baseline and at the exit visit. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (y-GT), and Alkaline Phosphatase (ALP) Values at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected and evaluated for liver function, including measuring ALT, AST, y-GT, and ALP. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Serum Creatinine, Uric Acid, and Total Bilirubin Values at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected for a biochemical test of creatine, uric acid, and total bilirubin. Creatine and uric acid are evaluated for kidney function. The liver function test includes total bilirubin. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Serum Blood Urea Nitrogen (BUN), Fasting Blood Glucose (FBG), Sodium, Potassium, Chloride, Total Cholesterol, and Triglyceride Values at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Blood samples of participants were collected for biochemical tests of BUN, FBG, electrolytes, cholesterol, and triglycerides. The BUN test is primarily used to evaluate kidney function. Electrolytes include sodium, potassium, and chloride. Change from Baseline was calculated as the value at the exit visit minus the value at Baseline.

  • Number of Participants With Clinically Significant Abnormalities of Urinalysis at the Screening and Exit Visits [ Time Frame: Screening visit (-Week 1) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Urine samples of participants were collected for urinalysis, including measuring protein, blood, leukocyte, glucose, and urobilinogen. All values out of the normal range were evaluated by the investigator. Classification of clinically significant and not clinically significant was based on the investigator's clinical judgment; no specific criteria were used.

  • Mean Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at the Exit Visit [ Time Frame: Baseline (Day 0) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    Systolic blood pressure (SBP) and diastolic BP of participants were measured in the sitting position. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.

  • Mean Change From Baseline in Pulse Rate at the Exit Visit [ Time Frame: Baseline (Screening) and the exit visit (Week 12 or earlier) ] [ Designated as safety issue: No ]
    The pulse rate of participants was recorded. Change from Baseline was calculated as the value at the exit visit (Week 12 or earlier) minus the value at Baseline.


Enrollment: 109
Study Start Date: September 2010
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BTX-A
Botulinum toxin type A
Drug: Botulinum toxin type A
Botulinum toxin type A

Detailed Description:

This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for the treatment of patients with focal wrist, finger and in some cases, thumb spasticity post-stroke. Qualified patients will be eligible for enrollment upon completion of double-blind study 112958. Patients will receive a single treatment session with intramuscular injections of GSK1358820 "200U or 240U (if thumb spasticity is present)".The subjects will be observed for 12 weeks post injection.

Each completed subject will attend 4 clinic visits. The maximum study duration is 13 weeks. The study includes a 1 week pretreatment period, during which the screening visit (visit 1 could be the last visit of previous double-blind study 112958 or any time within 3 months after completion of previous study) is to take place. Only one upper limb (meeting inclusion/exclusion criteria) will be evaluated and treated in the study. Subjects will receive a single intramuscular treatment with investigated drug at day 0 (visit 2). There will be two post-injection follow-up visits at week 6 and 12 (visits 3 to 4).

  Eligibility

Ages Eligible for Study:   18 Years to 76 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Within 3 months after completion of the GSK/Allergan study 112958.
  2. Wrist flexor muscle tone of 2 or greater and finger flexor muscle tone of 1 or greater as measured on MAS (0 to 4).
  3. At least one functional disability item (i.e., hygiene, dressing, pain, or cosmesis) with a rating of 2 or greater on DAS (0 to 3).
  4. If using physical therapy, must be stable for at least 1 month prior to study enrolment in study 112958.
  5. >=40kg in weight.
  6. QTc criteria: (either QTcb or QTcf, machine or manual overread, males or females); include the following details as appropriate: QTc<450 millisecond (msec) or <480msec for subjects with Bundle Branch Block - values based on either single electrocardiogram (ECG) values or triplicate ECG averaged QTc values obtained over a brief recording period.
  7. Liver function tests: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2xULN; alkaline phosphatase and bilirubin ≤1.5xULN (isolated bilirubin >1.5ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  8. In the opinion of the investigator, subject must clearly understand the intent of the study and be willing and able to comply with study instructions and complete the entire study.
  9. Informed consent has been obtained

Exclusion Criteria:

  1. Presence of fixed contracture of the study limb (absence of passive range of motion).
  2. Profound atrophy of muscles to be injected (in the investigators opinion).
  3. Infection or dermatological condition at the injection sites.
  4. Significant inflammation in the study limb limiting joint movement.
  5. History of or planned treatment for spasticity with phenol or alcohol block in the study limb.
  6. History of or planned surgical intervention for spasticity of the study limb.
  7. History (within 3 months of qualification) of or planned (during study period) casting of the study limb.
  8. Participation in another clinical study (with the exception of study 112958) , within the 30 days immediately prior to enrolment.
  9. Planned or anticipated initiation of new antispasticity medications during the clinical study.
  10. Any medical condition that may put the subject at increased risk with exposure to GSK1358820, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might have interfered with neuromuscular function.
  11. Concurrent use of aminoglycoside antibiotics or other agents that might interfere with neuromuscular function. A full list of prohibited medications that interfere with neuromuscular transmission is provided as Appendix 1.
  12. Current treatment for spasticity with an intrathecal baclofen.
  13. Females who are pregnant, nursing, or planning a pregnancy during the study period, or females of childbearing potential, not using a reliable means of contraception.
  14. Known allergy or sensitivity to study medication or its components.
  15. Bedridden subjects.
  16. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  17. Presence of clinically unstable severe cardiovascular, renal or respiratory disease.
  18. Investigator's opinion that the subject has a concurrent condition(s) that may put the subject at significant risk, may confound the study results, or may interfere significantly with the conduct of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01205451

Locations
China, Hubei
GSK Investigational Site
Wuhan, Hubei, China, 430060
China, Jiangsu
GSK Investigational Site
Nanjing, Jiangsu, China, 210029
China, Sichuan
GSK Investigational Site
Chengdu, Sichuan, China, 610041
China
GSK Investigational Site
Hangzhou, China, 310016
GSK Investigational Site
Shanghai, China, 200025
GSK Investigational Site
Shanghai, China, 200040
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01205451     History of Changes
Other Study ID Numbers: 114609
Study First Received: September 3, 2010
Results First Received: July 19, 2012
Last Updated: November 15, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
GSK1358820
upper limb
spasticity
post-stroke

Additional relevant MeSH terms:
Muscle Spasticity
Stroke
Cerebral Infarction
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Botulinum Toxins, Type A
Botulinum Toxins
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 20, 2014